

What is claimed:

1. A free radical quenching composition comprising a liposome containing at least two members selected from the group consisting of beta-carotene, vitamin E, vitamin C, glutathione, niacin, and optionally at least one trace metal.

2. The composition according to claim 1, wherein said composition comprises beta-carotene, vitamin E, vitamin C, glutathione, and niacin, and optionally at least one trace metal.

3. The composition according to claim 1, wherein said trace metal is Zn, Se, Cr, Cu, or Mn.

4. A cream containing the composition according to claim 1 and a pharmaceutically acceptable carrier.

5. A lotion containing the composition according to claim 1 and a pharmaceutically acceptable carrier.

6. An injectable solution containing the composition according to claim 1 and a pharmaceutically acceptable carrier.

7. A tablet containing the composition according to claim 1 and a pharmaceutically acceptable carrier.

8. A method of delivering non-enzymatic antioxidants, comprising administering to a site in need thereof an effective amount of the composition according to claim 1 or 2 and optionally a pharmaceutically acceptable carrier.

9. A method for reducing the undesirable side effects of free radicals in a mammal, comprising administering to a mammal in need thereof an effective amount of the composition according to claim 1 and optionally a pharmaceutically acceptable carrier.

10. A method of treating inflammatory conditions in a mammal, comprising administering to a mammal in need thereof an effective amount of the composition according to claim 1 and optionally a pharmaceutically acceptable carrier.

11. A method of increasing the level of antioxidants in mammalian cells, comprising administering to mammalian cells in need thereof an effective amount of the composition according to claim 1 and optionally a pharmaceutically acceptable carrier.

12. A method of increasing the level of antioxidants in mammalian cells and/or organs which are *ex situ* awaiting transplantation, comprising administering to mammalian cells and/or organs in need thereof an effective amount of the

composition according to claim 1 and optionally a
pharmaceutically acceptable carrier.

5 13. A method of treating inflammatory conditions in a
mammal, comprising (a) diagnosing the clinical condition of said
mammal, (b) administering to said mammal in need thereof an
effective amount of the composition according to claim 1 and
optionally a pharmaceutically acceptable carrier, and (c)
10 monitoring the clinical condition of said mammal.